Charles River Laboratories pronostica un BPA ajustado para el tercer trimestre de entre 2,90 y 3 dólares, destacando menores volúmenes de modelos de investigación de América del Norte debido a los presupuestos planos de los NIH y la lentitud de las subvenciones. A pesar de estos obstáculos, la empresa sigue centrada en su estrategia de adquisiciones.

If Charles River Laboratories International sat on your watchlist rather than in your portfolio, the past year may feel like a missed chance. Holding Charles River Laboratories International over the past year would have returned 63.6%, including dividends. If you were staring at it on 2 October 2025, before that move, the key puzzle was simple. Could the company’s push into New Approach Methods and AI-enabled services really offset rising regulatory pressure on traditional animal...

If Charles River Laboratories International sat on your watchlist rather than in your portfolio, the past year may feel like a missed chance. Holding Charles River Laboratories International over the past year would have returned 63.6%, including dividends. If you were staring at it on 2 October 2025, before that move, the key puzzle was simple. Could the company’s push into New Approach Methods and AI-enabled services really offset rising regulatory pressure on traditional animal...

Fresh attention on Charles River Laboratories International (CRL) follows sector data showing the global animal model market projected at US$3.6b by 2032, alongside CRL’s 48.4% year-to-date gain relative to medical peers. In the short term, momentum has cooled, with the 7 day and 30 day share price returns both slightly negative after a strong 90 day gain of 25.8%. Charles River Laboratories International’s 1 year total shareholder return of 63.6% and 3 year total shareholder return of 50%...